Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer

Nivolumab, an anti-programmed cell death-1 monoclonal antibody, is currently used to treat many types of advanced cancers including recurrent and metastatic head and neck cancer. However, there are increasing reports concerning immune-related adverse events related to nivolumab therapy. Here, we report three patients who presented with adrenal insufficiency following nivolumab therapy. Two were diagnosed as having isolated adrenocorticotropic hormone (ACTH) deficiency and one was diagnosed as having primary adrenal insufficiency.

Source: Auris, Nasus, Larynx - June 20, 2019 Category: ENT & OMF Authors: Hiroki Kagoshima, Ryusuke Hori, Tsuyoshi Kojima, Yusuke Okanoue, Shintaro Fujimura, Atsushi Taguchi, Kazuhiko Shoji Source Type: research